Identification of an interleukin-15 antagonist peptide that binds to IL-15Rα

Biotecnologia Aplicada

Volumn 25, Issue 4, 2008, Pages 320-324

  Santos, Alicia ^a   Cabrales, Ania ^a   Reyes, Osvaldo ^a   Gerónimo, Haydee ^a   Rodríguez, Yunier ^a   Garay, Hilda ^a   Aurora Arrieta, Celia ^a   Silva, Ricardo ^a   Guillén, Gerardo ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Antagonist; Cytokine; IL 15; Peptide; Receptor alpha

Indexed keywords

ALANINE; CYSTEINE; CYTOKINE RECEPTOR ANTAGONIST; DIMER; FC RECEPTOR; HYBRID PROTEIN; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 6; LYSYLVALYLTHREONYLALANYLMETHIONYLLYSYLCYSTEINYLPHENYLALANYLLEUCYLLEUCINE; SERINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DIMERIZATION; DRUG MECHANISM; HUMAN; HUMAN CELL; INFLAMMATION; MALE; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 76749115205     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Waldmann TA. IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends Mol Med 2003;9: 517-21.
2. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T celldependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997;3:189-95.
3. Kirman I, Nielsen OH. Increased numbers of interleukin-15-expressing cells in active ulcerative colitis. Am J Gastroenterol 1996;91:1789-94.
4. Agostini C, Trentin L, Facco M, Sancetta R, Cerutti A, Tassinari C, et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996;157:910-8.
5. Kivisäkk P, Matusevicius D, He B, Söderström M, Fredrikson S, Link H. IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS). Clin Exp Immunol 1998;111:193-7.
6. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994;13:2822-30.
7. Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 1995;14:3654-63.
8. Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med 2004;7:825-34.
9. Budagian V, Bulanova E, Orinska Z, Ludwig A, Rose-John S, Saftig P, et al. Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem 2004;279:40368-75.
10. Budagian V, Bulanova E, Orinska Z, Pohl T, Borden EC, Silverman R, et al. Reverse signaling through membrane-bound interleukin-15. J Biol Chem 2004;279: 42192-201.
11. Frank R. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports-principles and applications, J Immunol Methods 2002;267:13-26.
12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RTPCR. Nucleic Acids Res 2001;29:e45.
14. Reineke U, Volkmer-Engert R, Schneider-Mergener J. Applications of peptide arrays prepared by the SPOT-technology. Curr Opin Biotechnol 2001;12:59-64.
15. Bernard J, Harb C, Mortier E, Quéméner A, Meloen RH, Vermot-Desroches C, et al. Identification of an interleukin-15alpha receptor-binding site on human interleukin-15. J Biol Chem 2004;279: 24313-22.
16. Anderson DM, Kumaki S, Ahdieh M, Bertles J, Tometsko M, Loomis A, et al. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J Biol Chem 1995;270:29862-9.
17. Kobayashi H, Carrasquillo JA, Paik CH, Waldmann TA, Tagaya Y. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res 2000;60:3577-83.
18. Handisurya A, Steiner GE, Stix U, Ecker RC, Pfaffeneder-Mantai S, Langer D, et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 2001;49:251-62.
19. Budagian V, Bulanova E, Orinska Z, Ludwig A, Rose-John S, Saftig P, et al. Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem 2004;279:40368-75.
20. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 2001;7:1773-81.
21. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 1999;85:134-44.
22. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003;112: 1571-80.